Mark Keaton
Impact in
-
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
- Pancreatic and Hepatic Oncology Research
-
- Breast Cancer Treatment Studies
Papers in
- Oncology 15
- Cancer Treatment and Pharmacology 11
- HER2/EGFR in Cancer Research 7
- Colorectal Cancer Treatments and Studies 6
- Lung Cancer Research Studies 2
-
- Lung Cancer Treatments and Mutations 4
- Advanced Breast Cancer Therapies 3
- Co-authors
- Tarek Chidiac (3 shared papers)Thomas M. Cosgriff (3 shared papers)Myo Min (3 shared papers)Graydon Harker (3 shared papers)B. Mirtsching (3 shared papers)Barrett H. Childs (2 shared papers)John D. Hainsworth (3 shared papers)Andrew H. Ko (1 shared paper)
- Journals
- Journal of Clinical Oncology (7 papers)Clinical Breast Cancer (4 papers)Investigational New Drugs (2 papers)Annals of Oncology (1 paper)Genes & Diseases (1 paper)
- Partner nations
- United StatesUnited KingdomChina
In The Last Decade
Mark Keaton
16 papers receiving 252 citations
Peers
Comparison fields: 5 of 52
- Oncology 208
- Cancer Research 65
- Hepatology 19
- Pharmacology 19
- Pulmonary and Respiratory Medicine 67
Countries citing papers authored by Mark Keaton
This map shows the geographic impact of Mark Keaton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Keaton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Keaton more than expected).
Fields of papers citing papers by Mark Keaton
This network shows the impact of papers produced by Mark Keaton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Keaton. The network helps show where Mark Keaton may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark Keaton, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2011 | 58 | |
| 2 | 2011 | 49 | |
| 3 | 2014 | 47 | |
| 4 | 2011 | 25 | |
| 5 | 1988 | 19 | |
| 6 | 2011 | 16 | |
| 7 | 2009 | 10 | |
| 8 | 2014 | 9 | |
| 9 | 2017 | 5 | |
| 10 | 2015 | 5 | |
| 11 | 2006 | 4 | |
| 12 | 2008 | 4 | |
| 13 | 1990 | 2 | |
| 14 | 2017 | 2 | |
| 15 | 2009 | 2 | |
| 16 | 2009 | 1 | |
| 17 | 2008 | 0 |
About Mark Keaton
Mark Keaton is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology and Radiology, Nuclear Medicine and Imaging, having authored 17 papers that have together received 258 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (11 papers), HER2/EGFR in Cancer Research (7 papers), Colorectal Cancer Treatments and Studies (6 papers), Lung Cancer Treatments and Mutations (4 papers), Breast Cancer Treatment Studies (3 papers), Advanced Breast Cancer Therapies (3 papers), Monoclonal and Polyclonal Antibodies Research (2 papers) and Lung Cancer Research Studies (2 papers). The work is most often cited by research in Oncology (208 citations), Cancer Research (65 citations), Hepatology (19 citations), Pharmacology (19 citations) and Pulmonary and Respiratory Medicine (67 citations). Mark Keaton has collaborated with scholars based in United States, United Kingdom and China. Frequent co-authors include Tarek Chidiac, Thomas M. Cosgriff, Myo Min, Graydon Harker, B. Mirtsching, Barrett H. Childs, John D. Hainsworth, Andrew H. Ko, Eric K. Rowinsky and Heinz‐Josef Lenz. Their work appears in journals such as Journal of Clinical Oncology, Clinical Breast Cancer, Investigational New Drugs, Annals of Oncology and Genes & Diseases.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.